Clinicopathological features and immunoprofile of 30 cases of Brenner ovarian tumors

Kondi-Pafiti, A; Kairi-Vassilatou, E; Iavazzo, Christos; Vouza, Emmanouela; Mavrigiannaki, P; Kleanthis, C.-H.; Vlahodimitropoulos, D.; Liapis, Angelos

doi:10.1007/s00404-011-2182-5

Cited by 33 publications

(25 citation statements)

References 10 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seidman and Khedmati [5] reported a similar percentage of Brenner tumors associated with mucinous component. Other smaller studies, including ours, reported a larger percentage of Brenner tumors with mucinous tumor reaching up to 30% [8,12]. This data, however, do not include Brenner tumors with small cysts and or gland-like structures, in part lined by mucinous epithelium that, in our study, accounted for an additional 20% of cases.…”

Section: Discussioncontrasting

confidence: 78%

Different staining patterns of ovarian Brenner tumor and the associated mucinous tumor

Roma

Masand

2015

Annals of Diagnostic Pathology

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 78%

Different staining patterns of ovarian Brenner tumor and the associated mucinous tumor

Roma

Masand

2015

Annals of Diagnostic Pathology

View full text Add to dashboard Cite

“…In the present case, massive pleural effusion might be due to both pseudo-Meigs' syndrome and metastasis from the borderline mucinous cystadenocarcinoma derived from proliferative BT through metaplasia. Immunohistochemical profiles of the borderline mucinous cystadenocarcinoma and proliferative BT were same (positive for CK 7 and negative for CK 20) [11]. In addition, cytological findings of the pleural effusion were similar to those of the imprint cytology for the tumor.…”

Section: Discussionmentioning

confidence: 51%

Proliferative Brenner Tumor with Borderline Mucinous Cystadenocarcinoma of the Ovary in a 75-Year-Old Woman

Niwa¹,

Makino²,

Yamaguchi³

et al. 2014

OJPathology

View full text Add to dashboard Cite

We report here an extremely rare case of proliferative Brenner tumor with borderline mucinous cystadenocarcinoma of the ovary, metastasizing to the pleura in a 75-year-old woman. Massive pleural effusion were present due to metastasis and pseudo-Meigs' syndrome. The cytological findings from pleural effusion, ascites and tumor imprint were similar, suggesting mucus-producing malignant tumors. After receiving a thoracic drainage for pleural effusion, the patient underwent an exploratory laparotomy to remove the left-ovarian tumor. Histopathological examination revealed proliferative Brenner ovarian tumor with borderline mucinous cystadenocarcinoma, and immunohistochemical examinations for the tumors, even mucus-rich tumor cells were positive for CK 7 and negative for CK 20, suggesting the tumor arising from transitional cells, not from mucus-producing ovarian surface epithelial tumor cells. She underwent four courses of chemotherapy with paclitaxel and carboplatin. The patient showed no signs of recurrence 16 months after the surgery.

show abstract

“…Brenner tumors (BT) are rare and account for approximately 1%‐2% of all ovarian tumors. While the vast majority of BTs are benign, around 2%‐5% are borderline and malignant variants .…”

Section: Introductionmentioning

confidence: 99%

Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology

Pfarr

Darb‐Esfahani

Leichsenring

et al. 2017

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

Brenner tumors (BT) are rare ovarian tumors encompassing benign, borderline, and malignant variants. While the histopathology of BTs and their clinical course is well described, little is known about the underlying genetic defects. We employed targeted next generation sequencing to analyze the mutational landscape in a cohort of 23 BT cases (17 benign, 2 borderline, and 4 malignant) and 3 ovarian carcinomas with transitional cell histology (TCC). Copy number variations (CNV) were validated by fluorescence in-situ hybridization (FISH) and quantitative PCR-based copy number assays. Additionally, we analyzed the TERT promotor region by conventional Sanger sequencing. We identified 25 different point mutations in 23 of the analyzed genes in BTs and 10 mutations in 8 genes in TCCs. About 57% percent of mutations occurred in genes involved in cell cycle control, DNA repair, and epigenetic regulation processes. All TCC cases harbored TP53 mutations whereas all BTs were negative and none of the mutations observed in BTs were present in TCCs. CNV analysis revealed recurrent MDM2 amplifications in 3 out of 4 of the malignant BT cases with one case harboring a concomitant amplification of CCND1. No mutations were observed in the TERT promoter region in BTs and TCCs, which is mutated in about 50%-75% of urothelial carcinoma and in 16% of ovarian clear-cell carcinomas. In conclusion, our study highlights distinct genetic features of BTs, and detection of the triplet phenotype MDM2 amplification/TP53 wt/TERT wt may aid diagnosis of malignant BT in difficult cases. Moreover, selected genetic lesions may be clinically exploitable in a metastatic setting.

show abstract

Clinicopathological features and immunoprofile of 30 cases of Brenner ovarian tumors

Cited by 33 publications

References 10 publications

Different staining patterns of ovarian Brenner tumor and the associated mucinous tumor

Different staining patterns of ovarian Brenner tumor and the associated mucinous tumor

Proliferative Brenner Tumor with Borderline Mucinous Cystadenocarcinoma of the Ovary in a 75-Year-Old Woman

Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology

Contact Info

Product

Resources

About